Their expression is associated with an overall poor survival probability in ovarian, liver and lung cancer supporting the notion that SRF/IGF2BP1-enhanced gene expression is a conserved driver of oncogenesis that promotes both tumor growth and metastasis (6,26). This evidence concerns the gene IGF2BP1 and lung carcinoma.